Ad-hoc: Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million
Ad-hoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Ad-hoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 61.607 no-par value bearer shares at an issue price of EUR 17,50 per share
Ad-hoc: Marinomed Biotech AG: Agreement on the key terms of the issue of a secured EUR 2.5mn convertible bond
Public Relations